Olema pharmaceuticals, inc.OLMA.US Overview
OLMA Overall Performance
OLMA AI Analysis & Strategy
OLMA Recent Performance
8.34%
Olema pharmaceuticals, inc.
0.81%
Avg of Sector
-1.14%
S&P500
OLMA PowerScanner
OLMA Key Information
OLMA Valuation Metrics
OLMA Earnings Table
OLMA Profile
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.